EP4129983A4 - Forme cristalline d'un promédicament de nitroxoline, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée - Google Patents

Forme cristalline d'un promédicament de nitroxoline, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée Download PDF

Info

Publication number
EP4129983A4
EP4129983A4 EP21781348.4A EP21781348A EP4129983A4 EP 4129983 A4 EP4129983 A4 EP 4129983A4 EP 21781348 A EP21781348 A EP 21781348A EP 4129983 A4 EP4129983 A4 EP 4129983A4
Authority
EP
European Patent Office
Prior art keywords
production
pharmaceutical composition
crystalline form
nitroxoline
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP21781348.4A
Other languages
German (de)
English (en)
Other versions
EP4129983A1 (fr
EP4129983B1 (fr
Inventor
Liang Wu
Chen Zhou
Yijun Deng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Yahong Meditech Co Ltd
Asieris Pharmaceuticals Shanghai Co Ltd
Original Assignee
Jiangsu Yahong Meditech Co Ltd
Asieris Pharmaceuticals Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Yahong Meditech Co Ltd, Asieris Pharmaceuticals Shanghai Co Ltd filed Critical Jiangsu Yahong Meditech Co Ltd
Publication of EP4129983A1 publication Critical patent/EP4129983A1/fr
Publication of EP4129983A4 publication Critical patent/EP4129983A4/fr
Application granted granted Critical
Publication of EP4129983B1 publication Critical patent/EP4129983B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21781348.4A 2020-03-30 2021-03-30 Forme cristalline d'un promédicament de nitroxoline, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée Active EP4129983B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010236147 2020-03-30
PCT/CN2021/084057 WO2021197338A1 (fr) 2020-03-30 2021-03-30 Forme cristalline d'un promédicament de nitroxoline, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée

Publications (3)

Publication Number Publication Date
EP4129983A1 EP4129983A1 (fr) 2023-02-08
EP4129983A4 true EP4129983A4 (fr) 2024-03-13
EP4129983B1 EP4129983B1 (fr) 2024-12-25

Family

ID=77929313

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21781348.4A Active EP4129983B1 (fr) 2020-03-30 2021-03-30 Forme cristalline d'un promédicament de nitroxoline, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée

Country Status (12)

Country Link
US (1) US12583835B2 (fr)
EP (1) EP4129983B1 (fr)
JP (1) JP7780763B2 (fr)
KR (1) KR20230008047A (fr)
CN (1) CN115427397B (fr)
AU (1) AU2021245884A1 (fr)
BR (1) BR112022017437A2 (fr)
CA (1) CA3171261A1 (fr)
MX (1) MX2022011768A (fr)
TW (1) TW202144329A (fr)
WO (1) WO2021197338A1 (fr)
ZA (1) ZA202210075B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019351494B2 (en) * 2018-09-29 2025-03-13 Jiangsu Yahong Meditech Co., Ltd. Nitroxoline prodrug and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749406A (en) * 1983-10-18 1988-06-07 Ciba-Geigy Corporation Quinoline derivatives and compositions thereof for the protection of cultivated plants
US6933389B2 (en) * 2002-09-02 2005-08-23 Dr. Reddy's Laboratories Limited Process for preparation of crystalline form-1 of pantoprazole sodium sesquihydrate
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
US20130210821A1 (en) * 2010-05-27 2013-08-15 James E. Vath Methods for Treating Obesity
CN103282359A (zh) * 2010-12-17 2013-09-04 诺华股份有限公司 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式
CN103906744A (zh) * 2011-09-01 2014-07-02 葛兰素集团有限公司 新晶型
EP2970128B1 (fr) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Sels d'addition de base de nitroxoline et leurs utilisations
KR102209363B1 (ko) * 2016-03-31 2021-01-29 장슈 야홍 메디텍 코퍼레이션 리미티드 암 치료에서 니트록솔린 및 그의 유사체의 화학요법 및 면역요법과의 조합적 사용
CN106632255A (zh) * 2016-11-15 2017-05-10 临沂草之美医药科技有限公司 一种用于抗肿瘤药物凡德他尼组合物胶囊的凡德他尼化合物
CN110343090B (zh) * 2018-04-08 2021-06-04 威尚（上海）生物医药有限公司 喹唑啉衍生物盐型晶型及制备方法和应用
US10532047B2 (en) * 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
AU2019351494B2 (en) * 2018-09-29 2025-03-13 Jiangsu Yahong Meditech Co., Ltd. Nitroxoline prodrug and use thereof
CN111514142B (zh) 2020-05-29 2021-04-06 江苏亚虹医药科技股份有限公司 含硝羟喹啉前药的药物组合物及其制备方法和应用
CN111646936A (zh) 2020-06-22 2020-09-11 江苏亚虹医药科技有限公司 芳香醚类化合物的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
JP2023519276A (ja) 2023-05-10
TW202144329A (zh) 2021-12-01
ZA202210075B (en) 2025-01-29
CN115427397A (zh) 2022-12-02
AU2021245884A1 (en) 2022-09-29
KR20230008047A (ko) 2023-01-13
WO2021197338A1 (fr) 2021-10-07
EP4129983A1 (fr) 2023-02-08
BR112022017437A2 (pt) 2022-10-18
EP4129983B1 (fr) 2024-12-25
JP7780763B2 (ja) 2025-12-05
US12583835B2 (en) 2026-03-24
MX2022011768A (es) 2022-10-18
CA3171261A1 (fr) 2021-10-07
US20230119296A1 (en) 2023-04-20
CN115427397B (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
EP4134459C0 (fr) Superalliage à base de nickel et procédé de fabrication s'y rapportant et composant et application de celui-ci
EP4464704A4 (fr) Dérivé contenant un cycle pipérazino, sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation et son utilisation
EP4461735A4 (fr) Composé pour inhiber et dégrader irak4, composition pharmaceutique et application pharmaceutique associées
EP4563150A3 (fr) Nouvelles formes cristallines de n-(3-(2-(2-hydroxyéthoxy)-6-morpholinopyridin-4-yl)-4-méthylphényl-2(trifluorométhyl)isonicotinamide en tant qu'inhibiteurs de raf pour le traitement du cancer
EP4205745C0 (fr) Composition pharmaceutique de cariprazine, méthode de préparation et son application
EP4567032A4 (fr) Composé inhibiteur de kif18a, composition pharmaceutique et son procédé de préparation et son utilisation
EP3502113A4 (fr) Sel pharmaceutiquement acceptable d'inhibiteur d'egfr, forme cristalline de celui-ci, son procédé de préparation et son application
EP4053152A4 (fr) Kératine bd-13, procédé de préparation, composition pharmaceutique et utilisation de celle-ci
EP4434981A4 (fr) Composé à cinq et six chaînons, son procédé de préparation et composition pharmaceutique et son utilisation
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
EP4431513A4 (fr) Dérivé de carbamoylpyridone polycyclique, son procédé de préparation et composition pharmaceutique de celui-ci
EP4389752A4 (fr) Dérivé de camptothécine, composition pharmaceutique et leur utilisation
EP4129983A4 (fr) Forme cristalline d'un promédicament de nitroxoline, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée
EP4253376C0 (fr) Forme saline et forme cristalline d'un dérivé hétérocyclique contenant de l'azote, leur procédé de préparation et leur utilisation
EP4378955A4 (fr) Anticorps anti-dll3 et son procédé de préparation, conjugué de médicament et application associée
EP4249480C0 (fr) Composé diphénylpyrazole, son procédé de préparation et son application
EP3560921A4 (fr) Composé de quinazoline et procédé de préparation, utilisation et composition pharmaceutique correspondantes
EP4053159A4 (fr) Kératine bd-6, procédé de préparation, composition pharmaceutique et utilisation associée
EP4349831A4 (fr) Composé quinolinamine, son procédé de préparation et son utilisation dans des produits pharmaceutiques
EP4234548A4 (fr) Inhibiteur d'amine benzo ou pyridopyrimidine substitué, son procédé de préparation et son application
EP3892613C0 (fr) Forme cristalline d'un intermédiaire clé d'un inhibiteur de btk kinase et procédé de préparation associé
SA112330457B1 (ar) مشتقات فينيل- ايزواوكسازول وعملية تحضيرها
EP4342900A4 (fr) Dérivés de sesquiterpène et compositions pharmaceutiques de ceux-ci, leur procédé de préparation et leur utilisation
EP3901161C0 (fr) Molécule de promédicament dinucléotidique cyclique, son procédé de préparation et son utilisation
EP4484409A4 (fr) Composé donneur de no, son procédé de préparation, composition pharmaceutique le comprenant, et son utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221024

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0215280000

Ipc: A61P0035000000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602021023957

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07D0215280000

Ipc: A61P0035000000

A4 Supplementary search report drawn up and despatched

Effective date: 20240212

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/12 20060101ALI20240206BHEP

Ipc: A61K 31/47 20060101ALI20240206BHEP

Ipc: A61P 35/00 20060101AFI20240206BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240722

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021023957

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250326

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20250417

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250325

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1753697

Country of ref document: AT

Kind code of ref document: T

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602021023957

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241225

REG Reference to a national code

Ref country code: CH

Ref legal event code: H13

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251024

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250330

26N No opposition filed

Effective date: 20250926

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20250331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250330

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260324

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20260319

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260323

Year of fee payment: 6